Fan Y, Zhao Y, Huang D, Zhao J, et al. First-Line Tislelizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Extensive-Stage SCLC: A Long-Term Survival and Programmed Death-Ligand 1 Subgroup Analysis From the Randomized, Phase 3 RATIONALE-312 Trial. J Thorac Oncol 2026;21:103655.
PMID: 41796863